<DOC>
	<DOC>NCT03033927</DOC>
	<brief_summary>The purpose of this phase II study is to develop a test to predict response of pancreatic cancer to different chemotherapy regimens.</brief_summary>
	<brief_title>Predicting Effective Therapy in Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<criteria>Histological or cytological diagnosis of pancreatic adenocarcinoma, confirmed at MSKCC, AJCC stage IV disease at time of enrollment. Patient planning to receive treatment with FOLFIRINOX or gem/nabP chemotherapy, with or without investigational agents. Prior surgery, chemotherapy and/or radiation therapy for AJCC Stage IIII pancreatic adenocarcinoma is permitted. ECOG performance status 02. A minimum age of 18 years old. Prior chemotherapy for AJCC stage IV pancreatic adenocarcinoma Known to be HIV positive on antiretroviral therapy Prior organ allograft Any medical or psychiatric condition that may interfere with the ability to comply with protocol procedures</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Stage IV Pancreatic Cancer</keyword>
	<keyword>FOLFIRINOX</keyword>
	<keyword>gem/nab-P chemotherapy</keyword>
	<keyword>17-042</keyword>
</DOC>